Zacks Investment Research | Aug 08, 2017 10:51PM ET
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported a loss of 16 cents per share in the second quarter of 2017, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company had reported a loss of 14 cents per share.
The company generated no revenues in the reported quarter as had been the case in the year-ago quarter.
Shares of Achillion surged almost 28% in after-hours trading on Aug 8, as the company announced positive interim results on its most advanced factor D inhibitor pipeline candidate, ACH-4471. However, the stock has underperformed the industry year to date. The company’s shares lost 2.9% whereas the industry registered an increase of 8.7%.
Research and development expenses increased nearly 29% from the year-ago period to $18.3 million due to increased clinical trial costs related to pipeline candidate, ACH-4471. The increase in expenses also included higher manufacturing costs related to ACH-5528 and cost related to ophthalmic factor D inhibitor compounds in development. However, the increase was partially offset by a decrease in cost related to manufacturing of ACH-4471.
General and administrative expenses were up 4% to $5.4 million due to an increase in corporate legal fees and consulting fees, partially offset by a decrease in corporate taxes.
Pipeline Update
In April, Achillion initiated patient dosing in a phase II study, evaluating its key pipeline candidate, a factor D inhibitor, ACH-4471 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). The company completed three months of dosing during the quarter and entered a long-term extension trial.
The interim results from the study, announced together with the earnings release, showed clinically meaningful complement inhibition and a favorable tolerability profile for ACH-4471. The candidate has shown improvement in LDH, hemoglobin, fatigue score and other markers of response.
Moreover, the company plans to initiate a phase II study later this year on ACH-4471 in patients with C3G, a rare renal disorder, which includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN).
Meanwhile, Achillion is planning to advance a number of next-generation factor D inhibitors in preclinical or clinical studies by 2017 end.
Also, Achillion is evaluating a triple combination of simeprevir, odalasvir and AL-335 in a phase II OMEGA-1 study in patients with HCV genotype 1, 2, 4, 5, and 6 infection, with and without cirrhosis. The study is being conducted by Johnson & Johnson’s (NYSE:JNJ) subsidiary Janssen with data expected in the second half of 2017.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.